2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH SUSAN HALABI
Racial Disparities in Prostate Cancer Treatment and Outcomes

VIEW ALL PROSTATE CANCER VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH MICHAEL HOFMAN
Theranostic Approaches for Advanced Prostate Cancer

VIEW ALL IMAGING: PROSTATE VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH KARIM FIZAZI
ARAMIS - Efficacy and Safety of Darolutamide in nmCRPC

VIEW ALL nmCRPC VIDEOS

2019 ASCO GU Symposium

2019 ASCO GU Symposium

INTERVIEW WITH MATTHEW GALSKY
Combination Approaches with Immune-Checkpoint Blockade in Bladder Cancer

VIEW ALL BLADDER CANCER VIDEOS

Featured Videos

#AUA14 - Active surveillance, surgical management, and clinical outcomes of sporadic bilateral multifocal oncocytoma - Session Highlights

ORLANDO, FL USA (UroToday.com) - Bilateral multifocal oncocytoma (BMO) is often confused with Birt-Hogg-Dube because of the similarity with kidney lesions in radiological imaging. Daniel Su and colleagues presented on the clinical characteristics, diagnosis, management, and outcome of BMO patients at the National Cancer Institute.

The authors identified 29 patients from 1999 to 2013 for this retrospective review. Patients were followed with serial imaging and mostly managed with renal biopsy and active surveillance.

auaPatients with BMO had mean tumor diameter of 4.4cm and eGFR of 46ml/min. Average growth rate was 0.20cm per year in this population. The mean renal function decreased after 52 months of median follow up. The majority of patients were diagnosed via kidney biopsy and underwent partial nephrectomy.

The authors concluded that BMO is associated with chronic kidney disease and slower tumor growth. The authors also concluded that BMO can be diagnosed using kidney biopsy, and given its slower growth may be managed by active surveillance. Chronic kidney disease is important to consider in patients with sporadic bilateral multifocal oncocytoma. It would be interesting to perform the study in a larger sample to see if the decrease in renal function will progress in patients with this pathology.

Presented by Daniel Su, MD at the American Urological Association (AUA) Annual Meeting - May 16 - 21, 2014 - Orlando, Florida USA

National Cancer Institute, Bethesda, MD USA

Written by Garen Abedi, MD, University of California (Irvine), and medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 3 Issue 4

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe